Abstract:e18072 Background: Previous studies confirmed locally advanced oral or oropharyngeal squamous cell carcinoma (LA OSCC or OPSCC) patients (pts) with a pathological response had higher probability of survival in neoadjuvant settings. Several ongoing trials of neoadjuvant immunotherapy in head and neck cancer showed promising results. However, the optimal regimen remains unclear. This trial aimed to evaluate the efficacy and safety of neoadjuvant therapy with anti-programmed cell death 1 (PD-1) mAb tislelizumab and chemotherapy, followed by surgery and adjuvant radiotherapy/chemoradiotherapy in LA OSCC or OPSCC. Methods: In this phase II, single-arm study, eligible pts aged 18-80 diagnosed with stage III-IV (AJCC v8) resectable or potentially resectable LA OSCC or OPSCC received neoadjuvant therapy with tislelizumab (200 mg), albumin-bound paclitaxel (260 mg/m2), and cisplatin (60-75 mg/m2) Q3W for 2 cycles, followed by surgery and adjuvant radiotherapy or concurrent chemoradiotherapy. The primary endpoint was major pathologic response (MPR). Secondary endpoints included pathological complete response (pCR), objective response rate (ORR), event-free survival (EFS), overall survival (OS) and safety. Results: Thirty-one pts were enrolled from Mar 2022 to Nov 2022, and completed neoadjuvant therapy, with an ORR of 61.3% (19/31) and CR rate of 6.5% (2/31). Of the 31 pts, 29 pts (18 OSCC, 13 OPSCC) successfully underwent surgery with a median age of 57 (34-72) yrs, smoking history 75.9%, alcohol history 72.4% and 82.8% of male. The clinical stage III, IVA and IVB accounted for 24.1%, 48.3% and 27.6%, respectively. The MPR rate was 65.5% (19/29), of which the pCR rate was 41.4% (12/29). R0 resection rate reached 100%. For the per-protocol population, 58.6% pts (17/29) complaint of symptoms included pain, trismus, dysphagic, and speech disorders, all of them reached remission after 2 cycles of neoadjuvant therapy. No delay of surgery occurred. Grade 3-4 adverse events (AEs) occurred in 3 pts including 3.4% G3 leukopenia, 6.9% G3 anemia and 3.4% G4 thrombocytopenia and mostly chemotherapy related. Grade 1-2 AEs included 13.8% anemia, 3.4% thrombocytopenia, 17.2% leukopenia, 13.8% increased aminotransferase, 3.4% increased creatinine, 3.4% hyperglycemia, 27.6% anorexia, 3.4% vomiting, 3.4% diarrhea, 10.3% constipation, 6.9% rash, 100% alopecia and 17.2% fatigue. Conclusions: Neoadjuvant tislelizumab combined with chemotherapy yielded promising MPR and pCR rates with an acceptable safety proﬁle in LA OSCC or OPSCC. Further follow-up is needed to confirm the long-term efficacy. Clinical trial information: ChiCTR2200056354 .

A Phase II Trial of Chemoradiation Using Weekly Docetaxel for High-Risk Postoperative Oral Squamous Cell Carcinoma Patients

Postoperative radiotherapy with docetaxel versus cisplatin for high-risk oral squamous cell carcinoma: a randomized phase II trial with exploratory analysis of ITGB1 as a potential predictive biomarker

Neoadjuvant Dose-Modified Docetaxel in Squamous Cell Carcinoma of the Head and Neck: A Phase 3 Study

A Study of Concurrent Chemoradiotherapy with Weekly Docetaxel and Cisplatin for Advanced Esophageal Squamous Cell Carcinoma with T4 And/or M1 Lymph Node Metastasis or Locoregional Recurrence

A Study of Weekly Docetaxel and Carboplatin As First-Line Chemotherapy for Advanced Non-Small Cell Lung Cancer.

A Phase II Study of Concurrent Chemoradiotherapy with Paclitaxel and Cisplatin for Inoperable Esophageal Squamous Cell Carcinoma.

A Randomized Phase II Study of Docetaxel with or Without Vandetanib in Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN).

Neoadjuvant Tislelizumab Combined with Chemotherapy in Locally Advanced Oral or Oropharyngeal Squamous Cell Carcinoma: A Single-Arm, Phase II Trial

[Phase I/II clinical trial of weekly administration of docetaxel plus cisplatin for advanced non-small cell lung cancer].

A Phase II Randomized Controlled Trial: Definitive Concurrent Chemoradiotherapy with Docetaxel Plus Cisplatin Versus 5-Fluorouracil Plus Cisplatin in Patients with Oesophageal Squamous Cell Carcinoma

A Phase II Study of Concurrent Nab-Paclitaxel/carboplatin Combined with Thoracic Radiotherapy in Locally Advanced Squamous Cell Lung Cancer

Neoadjuvant Chemotherapy for Locally Advanced Oral Squamous Cell Carcinoma: A Single Center Study

Prospective, open, multicentre Phase I/II trial to assess safety and efficacy of neoadjuvant radiochemotherapy with docetaxel and cisplatin for esophageal carcinoma.

A Phase II Trial of Concurrent Chemoradiotherapy with Weekly Paclitaxel and Carboplatin in Advanced Oesophageal Carcinoma.

Cetuximab, Paclitaxel, Cisplatin and Concurrent Radiation in Chinese Patients with Locally Advanced Esophageal Squamous Cell Carcinoma: an Open-Label, Multicenter, Phase II Study.

Docetaxel and nedaplatin twice a week with concurrent definitive radiotherapy in inoperable esophageal squamous cell carcinoma: A phase I trial (GASTO-1021)

Phase Iii Study Comparing Standard Radiotherapy With Or Without Weekly Oxaliplatin In Treatment Of Locoregionally Advanced Nasopharyngeal Carcinoma: Preliminary Results

Postoperative Concurrent Chemoradiotherapy for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma: A Phase II Clinical Trial

Concomitant Chemoradiotherapy Using Docetaxel and Cisplatin for Unresectable Stage Iii Lung Squamous Cell Carcinoma

Induction chemotherapy with or without erlotinib in patients with head and neck squamous cell carcinoma amenable for surgical resection

Randomized Phase III Trial of Induction Chemotherapy with Docetaxel, Cisplatin, and Fluorouracil Followed by Surgery Versus Up-Front Surgery in Locally Advanced Resectable Oral Squamous Cell Carcinoma.